Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Seth J Orlow

Showing results (1-10 of 126) with videos related to

Pageof 13
Sort By:
Paediatric Drugs|October 12, 2007
Topical calcineurin inhibitors in pediatric atopic dermatitis: a critical analysis of current issuesSeth J Orlow
Dermatology Online Journal|September 12, 2006
Eccrine angiomatous hamartomaChicky Dadlani, Seth J Orlow
The Journal of Clinical Investigation|October 5, 2011
Informed reasoning: repositioning of nitisinone to treat oculocutaneous albinismPrashiela Manga, Seth J Orlow
Journal of the American Academy of Dermatology|October 20, 2023
An update on private equity acquisitions in dermatology, 2013 to 2022Aneesh Agarwal, Seth J Orlow
The Journal of Investigative Dermatology|January 13, 2023
Skin in the Game: An Analysis of Venture Capital Investment in Dermatology from 2002 to 2021Aneesh Agarwal, Seth J Orlow
JAAD International|July 5, 2023
Nonprofit funding in dermatology: A cross-sectional analysis in the United States, 2015 to 2019Aneesh Agarwal, Seth J Orlow
Experimental Eye Research|October 9, 2007
The ocular albinism type 1 gene product, OA1, spans intracellular membranes 7 timesMichio Sone, Seth J Orlow
Experimental Eye Research|September 13, 2005
Ocular albinism 1 protein: trafficking and function when expressed in Saccharomyces cerevisiaeLiliana Staleva, Seth J Orlow
Journal of the American Academy of Dermatology|February 5, 2005
Treatment of children and adolescents with methotrexate, cyclosporine, and etanercept: review of the dermatologic and rheumatologic literatureChicky Dadlani, Seth J Orlow
The Journal of Investigative Dermatology|June 15, 2012
Engineering a new mouse model for vitiligoPrashiela Manga, Seth J Orlow
Pageof 13

Showing results (1-10 of 126) with videos related to

Sort By:
Pageof 13
Paediatric Drugs|October 12, 2007
Topical calcineurin inhibitors in pediatric atopic dermatitis: a critical analysis of current issuesSeth J Orlow
Dermatology Online Journal|September 12, 2006
Eccrine angiomatous hamartomaChicky Dadlani, Seth J Orlow
The Journal of Clinical Investigation|October 5, 2011
Informed reasoning: repositioning of nitisinone to treat oculocutaneous albinismPrashiela Manga, Seth J Orlow
Journal of the American Academy of Dermatology|October 20, 2023
An update on private equity acquisitions in dermatology, 2013 to 2022Aneesh Agarwal, Seth J Orlow
The Journal of Investigative Dermatology|January 13, 2023
Skin in the Game: An Analysis of Venture Capital Investment in Dermatology from 2002 to 2021Aneesh Agarwal, Seth J Orlow
JAAD International|July 5, 2023
Nonprofit funding in dermatology: A cross-sectional analysis in the United States, 2015 to 2019Aneesh Agarwal, Seth J Orlow
Experimental Eye Research|October 9, 2007
The ocular albinism type 1 gene product, OA1, spans intracellular membranes 7 timesMichio Sone, Seth J Orlow
Experimental Eye Research|September 13, 2005
Ocular albinism 1 protein: trafficking and function when expressed in Saccharomyces cerevisiaeLiliana Staleva, Seth J Orlow
Journal of the American Academy of Dermatology|February 5, 2005
Treatment of children and adolescents with methotrexate, cyclosporine, and etanercept: review of the dermatologic and rheumatologic literatureChicky Dadlani, Seth J Orlow
The Journal of Investigative Dermatology|June 15, 2012
Engineering a new mouse model for vitiligoPrashiela Manga, Seth J Orlow
Pageof 13